Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alliance Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: ubrx who wrote (342)	4/14/1999 9:54:00 PM
From: ubrx	Read Replies (1) \| Respond to of 548

Dilution. I guess everyone knew that something has to be done to fund the three phase III trials. biz.yahoo.com Is this dilution figured in the current share price? Jim

To: ubrx who wrote (342)	4/15/1999 6:20:00 PM
From: Alok Sinha	Respond to of 548

All the three products Oxygent, Liquivent and Impagent are in Phase III. Imagent is the farthest along with an NDA expected late summer , early fall. Enrollment for Oxygent Phase II in Europe started last Dec, US enrollment may start in the next couple of months. Liquivent enrollment should be complete later this year. I don't think dilution means much for a $2.5 stock. I recall the last time ALLP did a secondary offering, the stock actually went up when they went on a road show. Regards Alok